Early evolocumab to slow plaque buildup in heart arteries after an acute coronary event
Tests evolocumab added to standard cholesterol treatment in people after an acute coronary syndrome.
Plain-language title generated from the registry record
Registry title: CAPRA-EVO: a Randomized Serial PCCT Trial of Early Evolocumab After ACS
Key facts
- Where
- Chengdu and Xi'an, ChinaSee the 2 sites
- Phase
- Phase 4
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 40 to 75 who had an acute coronary syndrome and a successful stent procedure, and whose LDL cholesterol is still too high.
- Age
- 40 to 75 years
- Sex
- All sexes can join.
- Disease stage
- Acute coronary syndrome (STEMI, NSTEMI or unstable angina) treated with a successful PCI, with plaque in other heart arteries not caused by this event.
- Earlier treatment
- Either any statin for at least 4 weeks with LDL-C 1.8 mmol/L (70 mg/dL) or higher, or no statin before with LDL-C 3.2 mmol/L (124 mg/dL) or higher. No PCSK9 inhibitor or strong CYP3A4 inhibitor in the last 12 months.
- Biomarker or test result
- LDL-C 1.8 mmol/L (70 mg/dL) or higher on a statin, or 3.2 mmol/L (124 mg/dL) or higher without a statin.
Main reasons for not taking part
- Earlier bypass surgery, valve surgery, or PCI before this event
- Complex bifurcation lesions (Medina 1,1,1)
- Kidney or liver problems (eGFR below 60 or ALT/AST more than 3 times the upper limit of normal)
- Uncontrolled heart failure (NYHA class III-IV) or dangerous heart rhythm problems
- Pregnancy or breastfeeding, or planning pregnancy within the next year
Read by machine on 13 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 75 years old?
Source: NCT07612774, who can take part
Where in China
- West China Hospital of Sichuan UniversityChengdu, ChinaContact: Xiaoyu WangTaking people
- Tangdu Hospital, Air Force Medical UniversityXi'an, ChinaContact: Yan LiNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- West China Hospital
- Trial code
- NCT07612774
- Record updated
- 7 October 2026
- Original description
The CAPRA-EVO trial is a single-center, randomized, open-label study with blinded endpoint assessment comparing early evolocumab plus standard lipid-lowering therapy versus standard-of-care lipid-lowering therapy in patients with acute coronary syndrome after successful percutaneous coronary intervention. The study will use serial photon-counting coronary computed tomography angiography at baseline and 52 weeks to assess changes in non-culprit coronary plaque burden and stenosis severity. Secondary outcomes include changes in high-risk plaque features, lipid and inflammatory biomarkers, cardiovascular events, and safety outcomes. The trial aims to determine whether early intensive LDL-C lowering with evolocumab can reduce coronary plaque progression and support PCCT-CCTA as a noninvasive tool for monitoring atherosclerotic plaque dynamics.Read full original descriptionShow less
A Multicenter, Randomized Controlled Comparison of Effect of Evolocumab Versus Standard Lipid Lowering Therapy on Plaque Progression in Patients With Acute Coronary Syndrome by Serial PCCT (CAPRA-EVO Trial)
The CAPRA-EVO trial is a single-center, randomized, open-label study with blinded endpoint assessment comparing early evolocumab plus standard lipid-lowering therapy versus standard-of-care lipid-lowering therapy in patients with acute coronary syndrome after successful percutaneous coronary intervention. The study will use serial photon-counting coronary computed tomography angiography at baseline and 52 weeks to assess changes in non-culprit coronary plaque burden and stenosis severity. Secondary outcomes include changes in high-risk plaque features, lipid and inflammatory biomarkers, cardiovascular events, and safety outcomes. The trial aims to determine whether early intensive LDL-C lowering with evolocumab can reduce coronary plaque progression and support PCCT-CCTA as a noninvasive tool for monitoring atherosclerotic plaque dynamics.
Inclusion: Eligible patients must meet the following criteria:; Age between 40 and 75 years; Diagnosis of ACS, including ST-elevation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI) or unstable angina (UA); Successful PCI treatment, with post-procedural TIMI grade 3 flow and residual stenosis <30% and atherosclerotic plaque presence in non-culprit coronary vessels (not attributed to this target event); Suboptimal LDL-C control: Patients must have received any statin treatment for at least 4 weeks, with an LDL-C level ≥1.8 mmol/L; or Statin-naive patients must have an LDL-C level ≥3.2 mmol/L; Agreement to complete baseline CCTA and laboratory tests within 7 days of enrollment and signed informed consent; Commitment to complete 52 weeks of follow-up.
Exclusion: Use of PCSK9 inhibitors (e.g., evolocumab, alirocumab) or potent CYP3A4 inhibitors (e.g., itraconazole) within the last 12 months; Known intolerance to statins, evolocumab, or other investigational drugs related to the study; History of coronary artery bypass grafting (CABG); History of valve surgery; History of PCI treatment before the index ACS event; Active autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus); Uncontrolled heart failure (NYHA class III-IV) or malignant arrhythmias; Known allergy or hypersensitivity to iodinated contrast media; Hyperthyroidism or active thyroid disease; Life expectancy of less than 1 year (e.g., due to advanced malignancy); Hepatic or renal insufficiency (eGFR <60 mL/min/1.73m² or ALT/AST >3 times the upper limit of normal); Complex bifurcation lesions (Medina 1,1,1); Pregnancy or breastfeeding (or plans for pregnancy within the next year); Participation in another interventional clinical trial within the past 3 months.